Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of... Read More

Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery CAESAREA, Israel , March 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor... Read More

CAESAREA, Israel , March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before... Read More

IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel , March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug... Read More

IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation gallery An independent study by Dr. Ava Kwong evaluated expanding the ICE3 study population to include triple negative breast cancer and younger patients Four additional independent abstracts were presented at the... Read More

This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan CAESAREA, Israel , March 17, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today... Read More

Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean follow-up of 4.2 and 4.0 years, respectively Data support continued move toward... Read More

Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand CAESAREA, Israel , Feb. 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by... Read More

Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category Hands-on ProSense® training featured during the SIO Mini Masterclass on Breast Cryoablation; the session was extremely well attended with presentations led by interventional oncology and breast cancer thought leaders FDA's decision on ProSense® market authorization for... Read More

Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel , Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with China's... Read More

Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on market authorization of ProSense® for early-stage breast cancer is expected in the first quarter of 2025. FDA Advisory Panel voted in favor of ProSense®'s benefit-risk profile for early-stage low risk breast cancer. Positive ProSense® results reported through 10... Read More

CAESAREA, Israel , Jan. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid... Read More

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Jan. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal,... Read More

ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025 CAESAREA, Israel , Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),... Read More

Data confirm previous results showing that ProSense ® cryoablation is highly effective for kidney tumors < 3 cm and a safe procedure for kidney tumors < 5 cm in people ineligible for surgery Interim results presented at the Israeli Urological Association Conference in Eilat, Israel ProSense ® is approved for benign and malignant kidney tumors in the U.S., Europe and numerous other countries CAESAREA, Israel , Dec. 5, 2024... Read More

FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , Nov. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today... Read More

Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablation CAESAREA, Israel , Nov. 25, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of... Read More

CAESAREA, Israel , Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market... Read More

PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists PRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than ICE3 Article published... Read More

FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel , Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory... Read More

Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA website FDA Advisory Panel providing recommendations and vote on information concerning the benefit-risk profile for a De Novo marketing submission of the IceCure ProSense ® Cryoablation System in early-stage low risk breast cancer scheduled for November 7, 2024 CAESAREA, Israel , Oct. 29, 2024... Read More

Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Oct. 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today... Read More

ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryoablation, radiofrequency, and microwave) wins EUSOBI Young Physician Scientist Competition – cryoablation demonstrates 94% complete rate of ablation IceCure exhibited ProSense® and conducted hands-on demos and Q&A sessions with... Read More

Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense ® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024 96.3% recurrence free rate for women treated with ProSense ® cryoablation and endocrine therapy; 100% of patients and treating physicians were satisfied with the cosmetic outcome. Lead study author, Dr. Richard E. Fine , is an ICE3 investigator and winner of... Read More

Liquid nitrogen- (LN 2 ) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage Independent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense® for indications that are approved in various markets across the world CAESAREA, Israel , Sept. 16, 2024 /PRNewswire/... Read More

Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer F DA decision regarding marketing authorization of ProSense® expected by early 2025 CAESAREA, Israel , Sept. 12, 2024 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of... Read More

Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming n ear-term regulatory and operating catalysts CAESAREA, Israel , Sept. 4, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an... Read More

Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields Over 50 patents issued and allowed worldwide for IceCure's platform cryoablation technology CAESAREA, Israel , Aug. 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by... Read More

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by... Read More

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was offered and that cryoablation is a safe, effective alternative to surgery and well-tolerated as an out-patient procedure CAESAREA, Israel , Aug. 14, 2024 /PRNewswire/ -- IceCure... Read More

CAESAREA, Israel , Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on... Read More

Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's ICE3 study which treated early-stage breast cancer patients Recurrence-free rates were 94.7%, 87.8%, and 81.8%, at 1, 2, and 3 years, respectively Study published in American Journal of Roentgenology was conducted at 7 U.S. institutions and led by Principal... Read More

Demand for minimally invasive breast cancer treatment was overarching theme of the conference In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recurrence free rate Another independent study led by Professor Kawamoto found 0% breast cancer local recurrence in five-year follow up ProSense® expected to gain further traction in Japan , as distribution partner Terumo Corporation... Read More

CAESAREA, Israel , July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price... Read More

Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and local tumor control 8.9% recurrence rate in population of 45 patients who had previously received various therapies... Read More

CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received marketing authorization from the United States Food and Drug Administration (the "FDA") for its next-generation single probe... Read More

Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel , June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's management,... Read More

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quarter of 2024, including data on patients with an average follow up of approximately 3 years $6.92 billion global kidney cancer treatment market in 2024 expected to reach $8.78 billion by 2029—ProSense® is approved for the treatment... Read More

Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and the general public will be welcome to participate and comment in the open public hearing IceCure welcomes a transparent public forum to share ICE3 study results and show how ProSense® cryoablation could potentially offer a... Read More

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 trial data Awaiting FDA Decision Independent studies performed globally continue to demonstrate ProSense®'s efficacy and safety across numerous indications Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel... Read More

CAESAREA, Israel , May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024... Read More

CAESAREA, Israel , May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's CEO, Eyal Shamir , will present via a fireside chat at the A.G.P / Alliance Global Partners ' Virtual Healthcare Company... Read More

Study published in the peer reviewed journal Breast Cancer Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation Strategic distribution partner of ProSense® in Japan , Terumo Corporation, expects to submit an application for regulatory clearance for breast cancer in the second half of 202 CAESAREA, Israel , May 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:... Read More

Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of the ASBrS, Dr. Michael Berry , presents data and states "cryoablation is ready for prime time" Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy Available... Read More

Conference call to be held today at 10:00 am Eastern Time ; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel , April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and... Read More

Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed a 510(k) submission... Read More

Overview of U.S. Commercial Strategy will be Discussed on Conference Call CAESAREA, Israel , March 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and... Read More

Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer Study represents largest cryoablation study of its kind in the U.S. for early-stage low-risk malignant breast tumors CAESAREA, Israel , March 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a... Read More

Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel , March 12, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumo rs by freezing as an alternative... Read More

CAESAREA, Israel , March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir , will present at the 34th Annual Oppenheimer Healthcare MedTech & Services... Read More

MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0 CAESAREA, Israel , March 4, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an... Read More

Session conducted by Dr. Rupa Renganathan , who performed India's first breast cancer cryoablation procedure with ProSense®; Expert interview with Dr. Hania Bednarski , who has performed cryoablation breast procedures since 2014 CAESAREA, Israel , Feb. 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that... Read More

Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation CAESAREA, Israel , Feb. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today... Read More

CAESAREA, Israel , Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced Eisuke Fukuma , MD, PhD, who has performed over 600 breast cryoablation procedures with ProSense®, will host events that feature ProSense®... Read More

IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation CAESAREA, Israel , Jan. 30, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food... Read More

IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in California , receiving enthusiastic response from interventional oncologists ICE3 trial data were central to the Breast Cryoablation Master Class taught by several ProSense® users, including Dr. Tomkovich, ICE3's Co- Principal Investigator, and Dr. Fine, ICE3 Investigator who has treated numerous participants CAESAREA, Israel , Jan. 29, 2024... Read More

ProSense® users speaking at the conference about cryoablation included ISVIR President Dr. Suyash Kulkarni , as well as Dr. Shuvro Roy-Choudhury CAESAREA, Israel , Jan. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today... Read More

CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the... Read More

U.S. sales continue to increase with 25% jump in ProSense® system and disposable probe sales in 2023 over prior year ICE3 study is set for completion and final data read out CAESAREA, Israel , Jan. 10, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to... Read More

Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evidence demonstrating cryoablation can activate the body's natural immune response by enhancing CD8+ T cells, which are an important arm of immune response Data support previous studies and suggest ProSense® may produce anti-cancer benefits in humans beyond tumor destruction during... Read More

Independent study published in Annals of Surgical Oncology concludes cryoablation is an oncologically safe and feasible minimally invasive procedure option in lieu of surgery for patients with early-stage, low-risk breast cancer Study's authors suggest the widespread use of screening mammography allows for earlier detection - and therefore increased customization of treatment, less aggressive management, reduced treatment... Read More

ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulations Breast cancer cryoablation is already performed in India with ProSense® CAESAREA, Israel , Nov. 29, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation... Read More

Independent study concluded: - IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100% - 92.4% of patients (N= 24) were discharged the day after cyroablation - The technology's ability to preserve renal function post-treatment is... Read More

ProSense® system and disposables sales continue upward trend compared to the equivalent prior year period Expanded regulatory footprint, growing body of evidenced-based data, and distribution agreements demonstrate an increasing acceptance of minimally invasive alternatives to standard of care cancer treatment ICE3 trial remains on track and expected to be completed in the first quarter of 2024 Conference call scheduled for... Read More

Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its ProSense® system Company seeks to complete the review process, establish special controls, and finalize classification of ProSense® CAESAREA, Israel , Nov. 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense®... Read More

CAESAREA, Israel , Nov. 8, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended... Read More

Independent, non-sponsored studies by doctors using ProSense® to treat cancers of the breast, lung, kidney, and musculoskeletal system, as well as endometriosis and fibroadenomas Growing body of scientific data, including 13 breast cancer studies, is expected to drive adoption ProSense® is approved for various indications in 15 countries including the U.S., Canada , Europe , Brazil , and China CAESAREA, Israel , Nov. 6, 2023... Read More

CAESAREA, Israel , Nov. 3, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), a developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in... Read More

ICE3 trial will be finalized in Q1 2024 IceCure's distributor in India , Novomed, exhibited ProSense® and received a high level of interest from doctors, clinics, and hospitals ProSense was used to perform India's first breast cryoablation procedure in June 2023 CAESAREA, Israel , Oct. 30, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a... Read More

Paper cites IceCure's ICE3 interim clinical study results as evidence of safety and efficacy of cryoablation in early-stage breast cancer CAESAREA, Israel , Oct. 25, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense ® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced... Read More

Disappearance of lesions and absence of residual malignant cells in Luminal-A group considered to be predictive for the complete effectiveness of the treatment This is the latest in a growing body of evidence presented by independent, non-sponsored doctors who use ProSense CAESAREA, Israel , Oct. 5, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a... Read More

Study was conducted in Spain with women who declined standard of care surgery ProSense is approved for the treatment of breast cancer throughout the European Union CAESAREA, Israel , Oct. 2, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor... Read More

Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomy Patients throughout the European Union have access to ProSense for the treatment of malignant and benign breast tumors CAESAREA, Israel , Sept. 22, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation... Read More

CAESAREA, Israel , Sept. 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the U.S. Food and Drug Administration ("FDA") has at this time denied the Company's De Novo Classification request for breast cancer which was submitted based on... Read More

ProSense is gaining commercial traction in Europe where it has CE approval for numerous malignant and benign tissue indications. Symposium presenters include Professor Francois Cornelis who used ProSense in an endometriosis study which demonstrated cryoablation's efficacy rate of 92.8% in avoiding secondary surgery and Professor Julien Frandon who conducted a feasibility study of ProSense with positive results in kidney,... Read More

$6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early interest in ProSense in South America's largest market CAESAREA, Israel , Sept. 5, 2023 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an... Read More

Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systems Immediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery... Read More

Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo, to exhibit the ProSense System to physicians seeking minimally invasive alternatives to lumpectomy CAESAREA, Israel , Aug. 21, 2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of... Read More

Company awaits FDA's response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery Renowned physician, Dr. Robert Ward , to participate on the Company's conference call scheduled for today at 10am EDT CAESAREA, Israel , Aug. 14, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive... Read More

CAESAREA, Israel , Aug. 7, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results as of and for the six months ended June 30, 2023 with a press release prior to... Read More

Strong interest in ProSense from healthcare providers in Canada strengthens market potential ProSense now approved throughout North America CAESAREA, Israel , July 24, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced... Read More

ProSense has CE mark of regulatory approval in the European Union Initial purchase of 2 ProSense Systems plus disposable cryoprobes and introducers CAESAREA, Israel , July 17, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor... Read More

IceCure CEO, Eyal Shamir , to present and conduct Q&A on Wednesday, June 21 st at 11:00 AM Eastern Time on Track 2 CAESAREA, Israel , June 13, 2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq: ICCM) (TASE: ICCM), (the "Company" or "IceCure"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, will participate in the... Read More

Latest system installation in IceCure's global commercial rollout of ProSense CAESAREA, Israel , May 31, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that ProSense was recently installed and inaugurated at Kovai Medical Center... Read More

Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the only Cryoablation System Used in a First-of-its-Kind Cryotherapy Continuing Medical Education (CME) course at the American Society of Breast Surgeons (ASBrS) 2023 Annual Meeting Where a Plan was Presented for a Proposed ASBrS Cryoablation Trial Regulatory Approval... Read More

CAESAREA, Israel , May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday,... Read More

CAESAREA, Israel , May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday,... Read More

IceCure's ProSense was the cryoablation system used in first-of-its-kind cryotherapy continuing medical education (CME) course High level of interest expressed in cryoablation from attending surgeons and from American Society of Breast Surgeons (ASBrS) leadership Plan presented for a proposed ASBrS Cryoablation trial during CME course CAESAREA, Israel , May 1, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE:... Read More

Physicians Attending the CME Course to Demo ProSense, Learn More About Breast Cryoablation, and Receive Hands-on Training Previously Published ICE3 Trial Interim Results will be Highlighted to Further Raise Awareness of Breast Cryoablation CAESAREA, Israel , April 24, 2023 - IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by... Read More

ProSense System among the two types of systems used in the study Pain-free survival rates of 93.75% at 6 months and 82.72% at 36 months post-procedure 190 million women globally live with endometriosis, for which there is no cure; current treatments aim to control symptoms Data presented at Society of Interventional Radiology 2023 Annual Scientific Meeting by lead investigator Francois H. Cornelis , MD, PhD CAESAREA, Israel... Read More

CAESAREA , Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announces that it has initiated a process to voluntarily delist its ordinary shares, no par value per share (the "Ordinary Shares"),... Read More

Rising Utilization of ProSense in the U.S. Market Generates Year-over-Year Consumable Revenue Growth Physician Adoption Continues to Grow Ahead of the FDA's Response to the Company's Application for Marketing Approval in Breast Cancer Indication Regulatory Approval Received in China for Commercial Use of IceSense3 Disposable Cryoprobes, to be Used in Combination with its IceSense3 Cryoablation System Console, Which was... Read More

This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approved by the NMPA Products to be distributed in China through agreement with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co. Ltd. Ongoing physician awareness and education efforts will potentially... Read More

Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg CAESAREA, Israel , March 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System, that destroys tumors by freezing as an alternative to surgical tumor removal, announced that it will release its full year financial and operational... Read More

Significant regulatory and reimbursement milestones achieved Positive interim clinical results for ProSense in the treatment of kidney tumors and breast cancer Fortified balance sheet with $23.6 million in cash and cash equivalents including short-term deposits as of December 31, 2022 ProSense System and disposable cryoprobe sales continue to increase in the U.S. CAESAREA, Israel , Feb. 9, 2023 /PRNewswire/ -- IceCure... Read More

Panel discussion included doctors currently using the ProSense cryoablation system Live ProSense demonstrations conducted at IceCure's booth CAESAREA, Israel , Jan. 26, 2023 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing, today announced its participation in the... Read More

Professional training courses are well-timed following IceCure's FDA filing for marketing authorization of ProSense with breakthrough indication CAESAREA, Israel , Jan. 25, 2023 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing, today announced that on January 13-14,... Read More

Patent has also been granted or allowed in major markets, including the European Union and Japan Cryogenic pump potentially broadens clinical indications for IceCure's cryoablation platform technology CAESAREA, Israel , Jan. 23, 2023 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys... Read More

Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowed Cryogenic pump enables multiple and longer duration procedures without the need to refill liquid nitrogen, potentially expanding clinical indications CAESAREA, Israel , Jan. 18, 2023 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation... Read More

CAESAREA, Israel , Jan. 4, 2023 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing, today released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir . Dear Shareholders, In 2022, we built a strong foundation for the road ahead. IceCure is... Read More

CAESAREA, Israel , Dec. 23, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the closing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the " Ordinary Shares ") priced at-the-market... Read More

CAESAREA, Israel , Dec. 21, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the pricing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the " Ordinary Shares ") priced at-the-market... Read More

CAESAREA, Israel , Dec. 20, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares. All of the securities to be sold in the offering are to be offered by IceCure. The proposed public... Read More

ICESECRET study interim findings presented at the Urological Association Conference in Eilat, Israel ProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgery ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe , and numerous other countries CAESAREA, Israel , Dec. 19, 2022 /PRNewswire/... Read More

Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel , Dec. 6, 2022 /PRNewswire/ -- I ceCure Medical Ltd . (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of... Read More

Conference call is scheduled for 8:00 a.m. EST today with guest speaker Dr. Hania Bednarski , oncoplastic breast surgeon and cryoablation specialist skilled in using the ProSense System Regulatory filings submitted in the United States for ProSense for treatment in breast cancer Achievement of Medicare coverage code for case-by-case reimbursement Regulatory approval received in Brazil for ProSense cryoprobes and introducers... Read More

Dr. Kenneth Tomkovich Presents: "To Freeze Or Not To Freeze? That Is The Question: Cryoablation For The Treatment Of Breast Cancer" Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation CAESAREA, Israel , Nov. 30, 2022 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the... Read More

CAESAREA, Israel , Nov. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30 , 2022 on Monday, December... Read More

CAESAREA, Israel , Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30 , 2022 on Monday, December... Read More